Anavex Life Sciences Corp. (AVXL)
Nasdaq: AVXL · Biological Products, (No Diagnostic Substances) · New York, NY · filing with the SEC since 2005
Who owns Anavex Life Sciences Corp.
As filed with the SECHolders of 5% or more
1
Vanguard Capital Management holds 5.03% of Common Stock, as its SCHEDULE 13G filed Jul 31, 2026 says.
Directors and officers
6
report now, of 11 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Vanguard Capital Management
SCHEDULE 13G · filed Jul 31, 2026 · Common Stock
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%
What AVXL reports owning in othersstakes of 5% or more, and other ties
3 subsidiaries in 3 countries, from the list filed with the 10-K filed Nov 25, 2025.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 6, 2025 to Nov 6, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2024 runs to Nov 6, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.